“Myopia Pipeline” report has been added to DelveInsight
Myopia Overview
Myopia (also known as Nearsightedness), occurs when the eye grows too long from front to back. The eye lens starts focusing the images in front of the retina instead of focusing on the retina. Therefore, people with myopia have well near vision but poor distance vision.
Myopia Pipeline
DelveInsight’s, “Myopia – Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request free sample copy– https://www.delveinsight.com/sample-request/myopia-pipeline-insight
Myopia Pipeline: Region Covered
Myopia Pipeline: Key Players
Myopia Pipeline: Drugs
Myopia Pipeline: Diagnosis
Undiagnosed cases may lead from headaches and strains to struggle for the clear visualization of the things in the distance.
Myopia Pipeline: Symptoms
The signs and symptoms for myopia include squinting, feeling fatigued when driving or playing sports along with headache and strain.
Myopia Pipeline: Report
An international team of vision scientists, some genes are involved in nerve cell function, metabolism, and eye development that have a small influence on myopia risk. The researchers have also found that individuals carrying greater numbers of the myopia-prone versions of the genes have up to tenfold increased risk of myopia.
Myopia Pipeline: Emerging Drugs Analysis
Many novel therapies are in the late stage of development, targeting a more effective approach for the treatment of Myopia. Upcoming therapies have the potential to start a new era in its treatment if and once approved.
Myopia Pipeline: Insights
Apart from these, Leo Lens Pharma announced in February 2020, that it received a notice of allowance from the USPTO for a patent for the use of its proprietary MediPrint process to manufacture a contact lens capable of providing enhanced myopia management. The novel product will allow patients suffering from, or at a high risk of developing, myopia to wear a contact lens that can automatically and continuously deliver a drug to control myopia, such as low dose Atropine, to the patient’s eye.
Myopia Emerging Drugs
MicroPine: Eyenovia
Atropine ophthalmic solution, known as MicroPine in US, is developed by Eyenovia, Inc. for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. It is designed based on Eyenovia’s Optejet microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP (microdose array print) to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of the drug is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. Atropine micro-formulation licensed to Arctic vision in China, Hong Kong, Macau, Taiwan and South Korea. Atropine micro-formulation licensed to Bausch Health in USA and Canada. The atropine micro formulation is being evaluated in Phase III clinical trials.
NVK002; Nevakar
Nevakar is developing NVK-002, a novel, investigational, preservative-free low-dose atropine eye drop which is administered nightly, as a single drop to both eyes. NVK-002 uses Nevakar’s proprietary technology, designed for maximum stability and tolerability. Nevakar is currently testing two concentrations in the US and Europe in multiple clinical studies. The product is being studied for up to 4 years to evaluate if it is safe and effective.
Myopia Pipeline Development Activities
The report provides insights into:
Table of content
Key questions answered in the report
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/